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2. Abbreviations  
ADAR2 adenosine deaminase acting on RNA 2 
aIP  apical intermediate progenitor 
AMPA  alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
AMPAR AMPA receptor 
APP  amyloid precursor protein 
Arc  activity-regulated cytoskeleton-associated protein 
aRG  apical radial glia 
ASD  autism spectrum disorder 
BDNF  brain-derived neurotropic factor 
bFGF  basic fibroblast growth factor 
bIP  basal intermediate progenitor 
BLBP  brain lipid binding protein 
BrdU  5-bromo-2-deoxyuridine 
bRG  basal radial glia 
BSA  bovine serum albumin 
Ca2+  calcium 
[Ca2+]i  intracellular calcium 
CaMKII Ca2+/calmodulin-dependent protein kinase II 
CNS  central nervous system 
CP-AMPAR calcium-permeable AMPAR 
DAG  diacylglycerol 
DAPI  4’,6-Diamidino-2-Phenylindole 
DCX  doublecortin 
DG  dentate gyrus 
DHPG  (S)-3,5-dihydroxyphenylglycine 
DMEM/F-12 Dulbecco’s modified Eagle’s medium nutrient mixture F-12 
E14  embryonic day 14 
E17  embryonic day 17 
EBSS  Earl’s balanced salt solution  
EGF  epidermal growth factor 
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ER  endoplasmic reticulum 
ESCs   embryonic stem cells 
FMR1  fragile X mental retardation 1  
Fmr1-KO Fmr1-knockout 
FMRP  FMR1 protein  
FXPOI  fragile X-associated primary ovarian insufficiency 
FXS  fragile X syndrome 
FXTAS fragile X-associated tremor/ataxia syndrome 
GABA  γ-aminobutyric acid 
GFAP  glial fibrillary acidic protein 
GLAST glial glutamate-aspartate transporter 
HBSS  Hank’s balanced salt solution  
hESCs  human embryonic stem cells 
hiPSCs human induced pluripotent stem cells 
ID  intellectual disability 
INM  interkinetic nuclear migration 
iGluR  ionotropic glutamate receptor 
IP3  inositol 1,4,5-trisphosphate 
IP3Rs   inositol triphosphate receptors 
iPSCs  induced pluripotent stem cells 
IP  intermediate progenitor 
KA  kainic acid 
[K+]e  extracellular potassium  
LRP  low-density lipoprotein 
LTD  long-term depression 
MAP1B microtubule-associated protein 1B 
MAP2  microtubule-associated protein 2 
mGluR metabotropic glutamate receptor 
miRNAs MicroRNAs 
MPEP  2-methyl-6-(phenylethynyl)-pyridine 
MZ  marginal zone 
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Naspm  naspm trihydrochloride 
NBQX  dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide 
NECs  neuroepithelial cells 
NGS  normal goat serum 
NMDA N-methyl-D-aspartate 
NMDAR NMDA receptor 
NPCs  neural progenitor cells 
O/N  overnight  
oSVZ  outer subventricular zone 
PBS  phosphate buffered saline 
P7  postnatal day 7 
PA1-1  plasminogen activator inhibitor 
i.p.  Intraperitoneal 
PFA  paraformaldehyde 
PhTx  philanthotoxin 
PPI  prepulse inhibition 
PSCs  pluripotent stem cells 
REST  RE1 silencing transcription factor 
RG  radial glia 
ROCs  receptor-operated channels 
RT  room temperature 
RyRs  ryanodine receptors 
SGZ  subgranular zone 
SNS  synaptoneurosomes 
SOCEs store-operated calcium entry channels 
STEP  striatal-enriched protein tyrosine phosphatase 
SVZ  subventricular zone 
Tbr2  t-box transcription factor 2 
tPA  tissue plasminogen activator 
TRPC  transient receptor potential type C 
Tuj1  anti-β-III-tubulin 
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VGCCs voltage-gated calcium channels 
vRG  ventricular radial glia 
VZ  ventricular zone 
WT  wild-type 
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3. Abstract 
Fragile X syndrome (FXS) is the most common cause of genetically acquired intellectual disability and 
is strongly associated with autism spectrum disorders. FXS is an X-linked neurodevelopmental disorder, 
with an incidence of approximately 1 in 5000 males and 1 in 8000 females. It is primarily caused by a 
trinucleotide repeat expansion in the Fragile X mental retardation 1 (FMR1) gene leading to epigenetic 
silencing and loss of FMR1 protein (FMRP). Studies using Fmr1-knockout (Fmr1-KO) mice, modelling 
FXS, revealed that alterations in glutamatergic signaling play a central role in the aberrances of 
developmental processes in FXS brain. Tissue plasminogen activator (tPA) is a serine protease that 
potentiates signaling mediated by glutamate receptors. This thesis explored the effects of tPA and 
glutamate receptor signaling during early differentiation of FXS neural progenitor cells (NPCs). The 
differentiation of human and mouse FXS NPCs was characterized using calcium imaging, live cell 
imaging and immunostaining. Expression of tPA was increased in NPCs and brain of Fmr1-KO mice. 
The increased tPA was involved in altered neuronal migration and activity-dependent changes in FMRP-
deficient mouse NPCs. NPCs were functionally characterized based on their responses to activation of 
type 1 metabotropic and ionotropic glutamate receptors. Increased differentiation of subpopulations of 
glutamate-responsive cells was observed in FXS NPCs. Treatment with 2-methyl-6-(phenylethynyl)-
pyridine (MPEP), rescued abnormal differentiation of glutamate-responsive cells in both human and 
mouse FXS NPCs. In addition, MPEP treatment corrected morphological defects and migration of Fmr1-
KO cells. Finally, an increased differentiation was evident for cells expressing calcium-permeable alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors in FXS NPCs and reduced 
GluA2 expression resulted in increased calcium permeability of AMPA receptors. In summary, this study 
provides insight into the molecular mechanisms involved in early aberrant differentiation of FXS 
neuronal cells and will pave the way to develop new therapeutic approaches and biomarkers for FXS. 
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4. Introduction  
The use of neural stem/progenitor cells (NPCs) has created novel possibilities for studies of brain 
development and disease mechanisms underlying disorders of the central nervous system (CNS). Many 
signaling pathways are involved in the regulation of stem cell proliferation and differentiation (1), 
making stem cell-based assays valuable for investigation of the developmental mechanisms. 
Furthermore, the remarkable discovery of reprogramming technologies provides an opportunity for the 
derivation of induced pluripotent stem cells (iPSCs) with patient-specific properties (2-5). The iPSCs can 
be used to model disorders (6-8) to improve understanding of disease pathophysiology and to develop 
targeted therapies. In this thesis, human iPSC (hiPSC)-derived and mouse brain-derived NPCs were used 
to model fragile X syndrome (FXS), which is the most common inherited cause of intellectual disability 
(ID) and a variant autism (9, 10). FXS is caused by a triplet CGG repeat expansion mutation in the 
Fragile X mental retardation 1 (FMR1) gene leading to the absence of FMR1 protein (FMRP) (11, 12). 
FMRP regulates translation of many mRNAs essential for maturation and function of synapses and 
neuronal networks (13). Exaggerated responses to metabotropic glutamate receptor (mGluR) activation 
and increased local protein synthesis at synapses (14, 15) are associated with the excitatory and inhibitory 
imbalance in FXS brain (16, 17). The role of FMRP in early brain development is poorly understood, as 
most studies on FXS are focused on mature neurons. Indeed, FMRP is highly expressed in NPCs (18-
20), and the early onset of FMR1 gene expression in the human fetal brain (18) indicates a crucial role 
for FMRP during early neuronal network formation. Previous studies have shown that the absence of 
FMRP results in abnormal differentiation and altered fate determination of FXS NPCs (21-25). In this 
context, this thesis contributes to broadening the understanding of glutamate signaling mediated effects 
on the early differentiation of NPCs lacking FMRP. 
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5. Review of the literature 
5.1 Stem cells 
Stem cells are characterized by their self-renewal (proliferation) ability and plasticity (differentiation). 
Their self-renewal ability preserves their undifferentiated state, even after numerous cycles of cell 
division. “Plasticity” refers to the capacity of cells to adapt their genetic expression profile and 
differentiate towards specific cell phenotypes. Stem cells divide asymmetrically to give rise to two cells: 
one identical to the mother cell that maintains the pool of stem cells; and the second undergoing 
differentiation, eventually becoming a specialized cell. Stem cell potency can be divided into totipotent, 
pluripotent, and multipotent. Totipotent stem cells derive from fertilized eggs or morula cells in early-
stage embryos, and can differentiate into all cell types of the three germ layers, including placental cells 
(26). Pluripotent stem cells (PSCs) are isolated from the inner cell mass of a blastocyst (27) and have the 
capacity to differentiate into all cell types, except placental cells (26, 27). PSCs can also be induced from 
adult somatic cells by transduction of pluripotency-inducing genes (2-5). Multipotent stem cells are 
isolated from fetus or adults and they can differentiate into limited cell types restricted to same/closely-
related tissues of origin (28).  
 
5.2 Neural stem/progenitor cells 
NPCs are multipotent stem cells derived from developing or adult mammalian CNS (29). Interest in 
NPCs soared when newly generated neurons were first identified in the dentate gyrus (DG) (30) and the 
subventricular zone (SVZ) of the lateral ventricles in the adult brain (31, 32). NPCs located in these 
neurogenic zones continue to produce neurons throughout life (30-32). In the prenatal period, 
neurogenesis exists throughout the brain (33, 34). In adulthood, NPCs are located in the subgranular zone 
(SGZ) of the DG in the hippocampus (30, 35) and the SVZ of the lateral ventricles (31, 32, 36). 
Thousands of new cells are generated every day, but the exact number varies with age (37). For example, 
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approximately 17,000 new cells are produced each day in the DG of peri-pubescent rats and 
approximately 9,000 new cells are produced each day in the DG of young adult rats (38). Inhibition of 
adult neurogenesis in rats and mice has been shown to alter their behavior and affect learning and memory 
(39, 40). Thus, not surprisingly, aberrant neurogenesis is implicated in several neurological disorders, 
including epilepsy (41), Alzheimer’s disease (42), Parkinson’s disease (43), and FXS (44, 45), 
highlighting the importance of NPC regulation. NPCs can self-renew and differentiate into committed 
neural cell types of the CNS, such as neurons, astrocytes, and oligodendrocytes. NPCs can be cultured 
in vitro in an undifferentiated state in the presence of epidermal growth factor (EGF) and basic fibroblast 
growth factor (bFGF) (36, 46, 47).  
 
5.3 Cortical neurogenesis 
The mammalian neocortex is a well-organized cellular architecture formed by the production and 
positioning of diverse neuronal populations. It controls nearly all aspects of behavior, including language, 
perception, and decision-making. The human neocortex contains an immense number of neurons—
approximately 16 billion (48). Cortical neurons can be divided into two major groups: glutamatergic 
excitatory neurons, and γ-aminobutyric acid (GABA)-ergic inhibitory interneurons. There are 
approximately five times more glutamatergic neurons than GABAergic neurons (49), which are 
supported by glial cells and blood vessels. During embryonic stages, the appropriate production and 
positioning of excitatory and inhibitory neurons define the proper function of the neocortex.  
 
During early cortical neurogenesis (figure 1), a monolayer of homogenous neuroepithelial cells (NECs) 
lines the ventricular cavity. NECs constitute the neural tube and are the precursors of all future neurons 
in the CNS, including neocortical neurons (50). NECs undergo symmetric division to produce two 
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daughter NECs at each division, thereby expanding the thickness and surface area of the cerebral wall 
forming the VZ. Most NECs are multipotent progenitor cells capable of transforming into apical radial 
glial (aRG) cells and generating the first group of neurons in the neocortex (51). aRG cells are defined 
by their characteristic bipolar morphology and by the initiation of the expression of astroglial markers, 
such as glutamate-aspartate transporter (GLAST), brain lipid binding protein (BLBP), and glial fibrillary 
acidic protein (GFAP) (52-54). The bipolar aRG cells stretch between the pial and VZ surface, with a 
long basal process pointing towards the pial surface and the short apical endfoot reaching the VZ surface 
(55, 56). At the early stages of neurogenesis, aRG cells divide symmetrically to produce two daughter 
cells at each division (57, 58). As neurogenesis progresses, they predominately undergo asymmetric 
divisions to self-renew and to produce a post-mitotic neuron, a basal progenitor termed as intermediate 
progenitor (IP) cell (59, 60), or an outer subventricular zone (oSVZ) progenitor termed as basal RG 
(bRG) (61).   
 
Figure 1: Cortical neurogenesis in human neocortex. During early development, neuroepithelial cells 
(NECs) generate additional NECs or give rise to the first group of neurons. As neurogenesis progresses, 
NECs elongate and transit to apical radial glial cells (aRGs). aRGCs expand the progenitor pool or 
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generate neurons directly or indirectly via intermediate progenitor cells (IPs), IPs further generate 
neurons. Apical intermediate progenitors (aIPs), progeny of aRGCs that are also known as short neural 
precursors, divide predominately symmetrically and produce two postmitotic neurons. Basal RG cells 
(bRGs) likely originate from apical RG cells (aRGs) through oblique division, which generates neurons 
outside the ventricular zone (VZ). aIPs, apical intermediate progenitors; aRGs, apical radial glial cells; 
bRGs, basal RG cells; CP, cortical plate; IPs, intermediate progenitor cells; IZ, intermediate zone; MZ, 
marginal zone; NECs, neuroepithelial cells; oSVZ, outer subventricular zone; SVZ, subventricular zone; 
VZ, ventricular zone. (Figure prepared by Peteri UK and Achuta VS).  
 
Basal progenitors form the second proliferative zone, the SVZ. In the SVZ, basal IP (bIP) cells undergo 
symmetric divisions and produce either two postmitotic neurons (60, 62, 63) or a pair of bIP cells, which 
can subsequently generate a pair of neurons (60, 63). The bIP cells can be distinguished from aRG cells 
by their expression of transcription factors such as t-box transcription factor 2 (Tbr2), or cut like 
homeobox 1 and 2 (64, 65). The majority of the VZ progenitors possess a long process extending towards 
the basal pial surface with a growth cone at their tips. However, a small subpopulation of VZ progenitors 
has been identified to have either a short basal process or no basal process. These apical IP (aIP) cells 
were previously termed as short neural precursors (66). They are molecularly distinct and display 
different cycle kinetics compared to RG cells (66). aIPs can directly give rise to postmitotic neurons 
within the VZ (67). Recently, distinct self-renewing bRG population was discovered in the oSVZ of 
developing human and ferret neocortices (68, 69). A small proportion of bRG progenitors is also 
identified in the SVZ of the mouse neocortex (61, 70). Unlike aRG cells, bRG cells possess only a basal 
process pointing towards the pial surface (68). In humans, only a small proportion of bRG cells divide 
into IP cells, whereas the vast majority of bRG cells self-renew (68). Therefore, the generation of neurons 
in the human neocortex is significantly increased by self-renewal of bRG cells (71). Production of 
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secondary NPCs is termed as “transit amplification”, and appears to be a defining feature in humans that 
might have contributed to the evolutionary expansion of the neocortex (72). 
 
The cortical plate develops between the deep subplate and the superficial marginal zone (MZ). It is a six-
layered structure formed by the neurons migrating out of the proliferative zones (73). The MZ develops 
into the future layer I and the migrating neurons arriving at the cortical plate form layers II-VI of the 
cortex in an inside-out manner. Thus, the newborn neurons migrate past the earlier-born neurons. The 
intermediate zone separates the cortical plate and SVZ. It exists only during corticogenesis and contains 
the myelinated afferent and efferent axons of the cortex in the mature brain (74). 
 
5.4 Modeling neural differentiation 
The neurosphere assay has been a valuable tool for studying NPC proliferation and differentiation as well 
as neural development in vitro. Neurospheres are heterogeneous, consisting of multipotent stem cells and 
restricted progenitor cells with different proliferative, self-renewal, and differentiation capacities (75). 
NPCs isolated from the lateral ventricles of embryonic mouse brain form a non-adherent spherical cluster 
of cells termed as “neurospheres” in the presence of EGF and bFGF (36, 46, 47). Upon removal of growth 
factors, the neurospheres adhere to the substrate and cells start to migrate out. Cells migrating out of the 
neurosphere cluster initially display GLAST-positive RG morphology with thick processes followed by 
maturing neuron-like cells with thin, lengthy processes that show immunoreactivity to makers of 
immature neurons (76, 77). Eventually, the cells migrating further away from the neurosphere cluster 
will become mature neurons. An identical behavior of differentiating cells has been reported with human 
fetal-derived neurosphere cultures (78). In addition to RG and neuron-like cells, astrocytes and pre-
oligodendrocytes are also identified in the culture system but to a lesser extent. Similarly, neurospheres 
generated from human embryonic stem cells (hESCs) have been shown to differentiate into neurons and 
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glia (79). The hESCs cultured in neural induction and proliferation medium in the presence of bFGF for 
42 days showed a temporal increase in expression for neuroectoderm markers (79), thus confirming the 
differentiation to neuroectodermal lineage. During differentiation, the majority of the migrating adherent 
populations displayed GFAP-positive RG morphology, MAP2-positive neuron-like morphology and 
very few astrocyte-like morphology (79). Also, the majority of the neurons showed immunopositivity to 
glutamate and few to GABA (79). The human FGF-responsive neurospheres are shown to expand slower 
after an extended period (50-60 days) of culturing (80); conversely, neurospheres cultured in a 
combination of EGF and FGF have longer proliferation capacity (34). Similar to any other culture system, 
neurosphere model has its limitations. Multiple factors like cell plating density, culture medium, the 
concentration of growth factors (can differentiate towards different lineages), the method of passaging 
(enzymatic or manual) and high passage number (loss of neurogenic potential) affect the proliferation 
and differentiation of NPCs (75). Notably, the NPCs generated from mouse cortex develop in similarly 
as they do in vivo (81). Thus, the neurosphere model can be considered as a model containing different 
progenitor populations to study neural development in vitro. 
 
5.5 Basis of calcium signaling 
5.5.1 Calcium ion  
Calcium ion (Ca2+) is termed as a universal second messenger that regulates many functions in the 
eukaryotic cell. In the course of evolution, Ca2+ ion has been chosen to act as an important universal 
carrier because of its high affinity to interact with biological molecules. It controls almost all aspects of 
cell life, starting from fertilization to terminal programmed cell death (82, 83). Various buffer and sensor 
proteins regulate the Ca2+ signal, the former by maintaining the intracellular Ca2+ concentration ([Ca2+]i) 
and the latter by activating distinct protein targets (82, 84). In resting conditions, Ca2+ concentration (1-
2 mM) outside the cell is 10,000-20,000 times higher than [Ca2+]i concentration (100 nM). The steep 
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concentration gradient maintained between the extracellular space and the cell interior is due to highly 
conserved transporters and the existence of several intracellular compartments (85, 86). Using the steep 
concentration gradient, Ca2+ controls a broad range of cellular functions, such as differentiation of 
specific cell types, muscle contraction, on and off mechanisms in cardiac cells, neuronal migration, and 
many other physiological functions (82, 83, 85). Unlike other secondary messengers, Ca2+ signals exhibit 
unique properties, i.e., programmed cell death and autoregulation at both pre- and post-transcriptional 
levels (83, 87). These diverse functions make Ca2+ ions important messengers and understanding the role 
of Ca2+ in cell function, and dysfunction, is vital.  
 
5.5.2 Neuronal Ca2+ influx toolkit 
Ca2+ signal controls numerous neuronal functions, including excitability, exocytosis of neurotransmitters, 
synaptic plasticity, and gene transcription (86, 88). Like many other cell types, neurons use both 
intracellular and extracellular Ca2+ for signal transduction. Ca2+ influx is primarily mediated by voltage-
gated calcium channels (VGCCs), receptor-operated channels (ROCs), store-operated calcium entry 
channels (SOCEs), and transient receptor potential type C (TRPC) channels (82, 85). VGCCs are 
activated in response to voltage changes across cell-surface membrane, ROCs are activated upon binding 
a neurotransmitter to the receptor and SOCEs are activated in response to the release of Ca2+ from the 
endoplasmic reticulum (ER) and store depletion. In addition to Ca2+ entry from extracellular space, 
inositol triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) mediate Ca2+ release from internal 
stores (82, 88). The IP3-mediated Ca2+ release is trigged by neurotransmitters such as glutamate, whereas 
RyRs can be activated by changes in the cytosolic Ca2+ concentration.  
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5.6 Glutamate 
Glutamate is considered to be a principal mediator of signal transmission at excitatory synapses in the 
CNS. It controls many aspects of mammalian brain function, such as cognition, memory, and learning 
(89, 90).  Glutamate acts post-synaptically through ionotropic glutamate receptors (iGluRs), which are 
subdivided into N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid (AMPA), kainate receptors, and mGluRs, as shown in table 1. In addition to its role at the synapse, 
glutamate regulates cell survival, proliferation, differentiation, and migration of cells during early neural 
development (91-93). Glutamate receptor activation causes changes in [Ca2+]i concentration in the 
postsynaptic cell, thereby triggering various signaling cascades. 
 
Table 1: Glutamate receptors, their subunit compositions, and signal transmission. 
 
AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; cAMP, cyclic adenosine 
monophosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; NMDA, N-methyl-D-aspartate; 
PLC, phospholipase C. 
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5.6.1 Glutamate receptors  
5.6.1.1 Metabotropic receptors 
The mGluRs are seven-transmembrane G protein-coupled glutamate receptors that are found both pre-, 
post-synaptically on neurons, and glial cells. The glutamate-binding site of mGluRs is present within a 
large extracellular N-terminal domain (94). Upon agonist binding, signal transduction is triggered by a 
conformational change and altering downstream signaling pathways (94, 95). The intracellular C-
terminal domain has been shown to mediate interactions with other proteins (96). Unlike iGluRs, mGluRs 
mediate slow excitatory and inhibitory neurotransmissions. The mGluR family can be divided into three 
groups (Group I-III) based on their amino-acid homology, agonist binding, and activated downstream 
secondary signaling cascades (97-99). Neuronal group I mGluRs (mGluR1 and mGluR5) are generally 
localized to the periphery of post-synaptic density (100, 101). Group II mGluRs (mGluR2 and mGluR3) 
are located extrasynaptically and involved in inhibition of neurotransmission (101, 102). Group III 
mGluRs (mGluR4, mGluR6, mGluR7, and mGluR8) are predominately located at the presynaptic active 
zone and function as inhibitory autoreceptors (103, 104). When activated, the group I mGluRs couple 
through Gq/G11 and stimulate phospholipase C leading to the subsequent generation of inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) (98, 99, 105). Both IP3 and DAG act as second messengers, 
the former by releasing calcium from intracellular stores that in turn controls various cellular process and 
the latter by activating protein kinase C that in turn enables many proteins by phosphorylation (98, 99, 
105). Group II and III mGluRs are coupled to inhibitory G-proteins (Gi/o) that inhibit adenylyl 
cyclase/protein kinase pathway leading to a decrease in intracellular adenosine monophosphate and 
resulting in altered gene expression, inhibition of voltage-gated Ca2+ channels, and activation of K+ 
channels (98, 99, 105). 
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5.6.1.2 Ionotropic receptors 
AMPA receptors (AMPARs) are widely expressed in the CNS and are known to mediate fast excitatory 
neurotransmission (106). In the presence of glutamate, AMPARs mediate entry of Na+ and Ca2+ into the 
cell. AMPARs are functional tetrameters formed by GluA1-4 subunits (89, 98, 107). The combination 
of subunits confers the properties of AMPARs, such as Ca2+ permeability, desensitization kinetics, and 
channel conductance (89, 97, 99). The subunits of AMPARs are encoded by separate genes Gria1-4. 
Further complexity is introduced by alternative splicing to two forms of each subunit, known as “flip” 
and “flop” forms (108). During development, the “flip” variant is highly expressed, whereas both variants 
are equally expressed in the mature brain. In the CNS, most of the AMPAR complexes contain GluA1 
and GluA2 subunits. The presence of the GluA2 subunit and its RNA editing determine Ca2+-ion 
permeability of the AMPARs (109-111). Edited GluA2 subunit forms Ca2+-impermeable channels, 
whereas unedited GluA2 channels are permeable to Ca2+ flow. The GluA2 subunit contains four 
membrane domains (M1-M4), and the glutamine/arginine (Q/R)-editing site is located on M2 domain. 
The Q/R-editing of Gria2 pre-messenger RNA by adenosine deaminase acting on RNA 2 (ADAR2) 
enzyme renders AMPARs impermeable to Ca2+ (109-111) . The Q/R-editing is almost 100% in the adult 
CNS and is necessary for survival (112). Higuchi et al. showed that ADAR2 knockout mice displayed 
altered AMPAR channel properties, including receptor desensitization and increased Ca2+ permeability, 
leading to seizures and premature death of the mice (112). AMPARs are assembled in ER and are 
transported to the plasma membrane. A significant proportion of edited GluA2 remains in the ER before 
been transported to the synapse (113). The exocytosis and endocytosis of AMPARs at synapses is a 
highly dynamic process. Increased rate of endocytosis results in long-term depression (LTD), whereas 
enhanced receptor exocytosis leads to synaptic potentiation (114, 115).  
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Kainate receptors are composed of two related sub-families, GluK1-3 formerly known as GuR5-7 and 
GluK4-5 formerly known as KA1-2 (97, 107, 116). Kainate receptors are widely expressed at both the 
pre- and post-synaptic membrane of the CNS (89, 117). They likely form heteromeric assemblies with 
one or more members of both sub-families. The GluK1-3 subunits can also form homomeric tetramers, 
whereas GluK4-5 requires GluK1, GluK2, or GluK3 to form functional heteromeric assemblies (89, 98, 
118). In addition, GluK1-3 subunits undergo alternative splicing and RNA editing thereby increasing the 
subunit variants and complexity (89, 98, 118). Compared to AMPARs, kainate receptors are fast acting, 
bind with a higher affinity, and recover from desensitization slowly (119).  
 
NMDA receptors (NMDARs) are a major type of ionotropic receptors, which are highly permeable to 
Ca2+ and also to Na+. The NMDAR family contains seven subunits NR1, NR2A-D, and NRA-B that are 
encoded by separate genes (97, 107, 120).  The NR1 subunit encodes three alternatively spliced exons 
resulting in eight functional splice variants with different properties and distribution. For functional 
NMDARs, a compulsory NR1 subunit must be present in two copies in the receptor complex (120), along 
with other subunits. Glutamate binds to the NR2 subunit (121). Glycine is a co-transmitter that binds to 
the NR1 subunit and promotes the function of the receptor (122). Binding of both glycine and glutamate 
in two copies is necessary for the optimal functioning of NMDAR. The activation of NMDAR is voltage-
dependent and mediated by AMPA/kainate receptor activation. In normal resting conditions, 
extracellular Mg2+ blocks most NMDARs. The activation of AMPA/kainate receptors results in the Ca2+ 
influx into the cell leading to removal of the internal Mg2+ and thereby allowing more Ca2+ into the cell. 
The entry of Ca2+ triggers both Ca2+-dependent and Ca2+-independent mechanisms, which regulate 
AMPARs at the synaptic membrane, synaptic strength, and gene expression (89, 99, 123).  
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5.6.2 Role of glutamate receptors in NPC regulation  
Glutamate is proposed to regulate neurogenesis directly through mGluRs or iGluRs expressed by the 
NPCs (90, 124). The AMPA/kainate receptors are the first iGluRs to appear during embryonic 
development and are expressed throughout the adult CNS (110, 125). NMDARs are also highly 
expressed in both developing and adult brain (120, 126, 127). However, they become functional at later 
stages compared to AMPA/kainate receptors (126). There is evidence that they exhibit Ca2+ responses 
and depolarizing currents when the NPCs have differentiated into postmitotic neurons (126, 127). 
NMDAR activation is important for neuronal migration and neurite extension/retraction (127, 128). In 
mouse embryonic (E13-E18) cortical slice cultures, cell migration from proliferative zones (VZ/SVZ) 
towards CP is shown to be promoted by NMDARs and mGluRs, but not by AMPA/kainate receptors 
(127). Preventing NMDAR function partially blocks the glutamate-mediated migratory effect (127), 
indicating the involvement of NMDARs in migration. In embryonic mouse NPCs cultures, a 
subpopulation of cells responsive to NMDAR also responded to GABA receptor activation and exhibited 
enhanced migration in the presence of BDNF (129). The majority of cells in mouse NPCs cultures do 
express mGluRs and AMPA/kainate receptors (76, 77, 129). Blocking the AMPA/kainate receptor 
function by 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX) in vitro reduced the motility of NPCs (76). 
Also, blocking AMPAR function has been shown to regulate the extension of neurite processes in human 
fetal NPCs and human neuroblastoma cell line (130). 
 
All mGluRs, apart from mGluR6, are expressed in NPCs and/or neuronal cells in both embryonic and 
adult brain (105, 131). Several studies have reported the involvement of mGluR5 in the regulation of cell 
proliferation, survival, and migration (76, 131-134). Blocking mGluR5 function with 2 -methyl-6-
(phenylethynyl)-pyridine (MPEP) reduces cell proliferation and increases cell death in rat embryonic 
(E20) forebrain NPCs (132, 133), and a similar adverse effect of MPEP has been shown in the SVZ of 
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intact adult mice (132). Appropriately, the group I mGluR agonist (S)-3,5-dihydroxyphenylglycine 
(DHPG) has been shown to promote cell proliferation in both mouse and human-derived cortical NPCs 
(133, 134). In mouse embryonic NPCs cultures, MPEP treatment has been shown to flatten and distort 
RG processes and transiently promote the motility pattern of neuron-like cells (76). The role of group II 
and III mGluRs in both embryonic and adult neurogenesis seems to be less clear, however. Most studies 
conducted on group II and III mGluRs have shown that activation of these receptors has negative effects 
on NPC proliferation and neuronal differentiation (135, 136), whereas, few studies have reported that 
mGluR3 and mGluR7 promote cortical NPC proliferation (132, 137, 138).  
 
5.7 Tissue plasminogen activator 
Tissue plasminogen activator (tPA) is a serine protease that catalyzes the conversion of plasminogen into 
proteinase plasmin. In the vascular system, tPA is primarily responsible for the removal of intravascular 
fibrin deposits (139), as a result, it is used as a thrombolytic agent for stroke and myocardial infarction 
(140, 141). Besides its role in the vascular system, tPA has been implicated in synaptic plasticity, learning 
and excitotoxic cell death (142, 143). In human CNS, tPA is widely expressed in neurons and glial cells 
of neocortex, hippocampus, cerebellum, hypothalamus, thalamus, medulla, and sympathetic ganglia 
(144). tPA exerts its functions in an either plasmin-dependent or -independent manner. The plasmin-
dependent mechanisms include the conversion of the precursor form of brain-derived neurotropic factor 
(proBDNF) to mature form of BDNF, a crucial step in neuronal maturation and plasticity (145). The 
synaptic functions and excitotoxic effects exerted by tPA are known to be mediated via NMDAR 
signaling, which occurs both dependent and independent of plasminogen activation (146-148). In 2000, 
Nicole et al. first demonstrated that tPA directly cleaves the NR1 subunit and thereby increases the Ca2+ 
permeability of NMDAR in a plasmin independent manner (146). Subsequently, the mutation of 
Arginine260 within the NR1 subunit was shown as the tPA-mediated cleavage site (149). However, the 
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observations reporting the interplay between tPA and NMDAR remained controversial since the cleavage 
of NR1 subunit by tPA was shown to be an indirect effect, and in fact mediated by plasmin (147). Later, 
Samson et al. demonstrated the involvement of low-density lipoprotein (LRP) co-receptor in augmenting 
the NMDA-induced [Ca2+]i changes caused by tPA (148). Supporting the plasmin-mediated mechanisms, 
few other groups reported the cleavage of N2 subunit of NMDAR by tPA. The cleavage is shown to 
occur at two sites of the N2 subunit-Lys317 on N2A (150) and Arg67 on the N2B subunit (151) and 
thereby enhancing NMDAR activity. Whatever the mechanism, all these studies indicate that tPA 
increases NMDAR signaling. Thus, tPA plays a vital role in synaptic plasticity, either by proteolytic and 
nonproteolytic mechanisms involving pro-neurotrophins, NMDAR signaling, or via LRP. Besides, tPA-
deficient mice are shown to be resistant to experimentally induced neuronal degeneration (143). tPA is 
also implicated in CNS pathologies, including Alzheimer’s disease, infarct formation/injury, stroke, and 
seizure spreading (142).  
 
5.8 Micro RNA 
MicroRNAs (miRNAs) are a class of short non-coding RNAs generated from long precursor RNA 
transcripts through a series of cleavage steps. miRNAs are 18-25 nucleotides long RNAs, which plays a 
crucial role in regulating gene expression posttranscriptionally. miRNAs bind to a short core sequence 
in the 3’ untranslated region of its target mRNAs or non-coding RNAs (152) and results in mRNA 
degradation or repression of their translation. In 1993, Lee et al. first discovered lin-4 miRNA, which 
inhibits LIN-14 activity in Caenorhabditis elegans (153). Since then, over 2000 miRNAs have been 
identified in humans, and thought to control ˃ 60% of human protein-coding genes (154). miRNAs are 
known to regulate many cellular functions including proliferation, differentiation, and apoptosis (155). 
It is estimated that one-third of the human genes are regulated by miRNAs and alterations in their 
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expression (overexpression or repression) leads to disease states. miRNAs are implicated in many 
neuropsychiatric and neurodevelopmental disorders such as Schizophrenia, Tourette’s syndrome, ASD, 
Rett syndrome, FXS and Down syndrome (156). Thus, activation or inhibition of miRNAs became a 
promising tool in the area of therapeutics (157). 
    
5.9 Fragile X Syndrome 
FXS is a monogenic leading cause of intellectual impairment and is frequently associated with autism 
spectrum disorder (ASD) (158). The prevalence of FXS in the general population is approximately 1 in 
5000 males and 1 in 8000 females (159). The average age of diagnosis is 35-37 months (boys) and 41.6 
months (girls) (160). The life expectancy of FXS patients is normal; however, they need support and care 
throughout their lives. Due to its X-linked heritability, males are more frequently affected than females. 
Males present with severe symptoms/features, including developmental delay, hyperactivity, cognitive 
and memory impairments, epilepsy, mild facial dysmorphology such as long face and prominent ears, 
macroorchidism (161) and a unique pattern of neuropsychiatric features. Because of random inactivation 
of X chromosome, cognitive disability in the phenotype of FXS females is generally milder than males 
but it associates with emotional problems (162). Currently, there is no targeted treatment for FXS, but 
most procedures are to help to minimize the disease condition. These include proper education, therapy, 
and medications that improve individual capabilities and skills. The pharmacological treatments 
prescribed are on individual basis to lessen symptoms of anxiety, aggression and attention deficit 
hyperactivity disorder (ADHD). Treatment commonly used for FXS patients include stimulants, 
selective serotonin reuptake inhibitors (SSRIs), and antipsychotics (163). 
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5.9.1 Identification of FXS 
FXS is also known as Martin-Bell syndrome, named after Martin and Bell who first reported the sex-
linked inheritance of mental retardation in families in 1943 (164). More than two decades later, Lubs 
identified a fragile site in the long arm of X chromosome in a family, diagnosed with ID (165). Later, 
Sutherland found that the ability to visualize the fragile site depended on the specific culturing conditions 
with reduced folate (166). The exact location of the fragile site is found to be Xq27.3 (167), and the gene 
mapped to the constriction site is cloned and termed “FMR1 gene” (11). In most cases, the causative 
mutation is an expansion of CGG repeats (˃200) within the 5’untranslated region of the FMR1 gene 
leading to promoter methylation and the absence or deficiency of FMRP (11). In normal individuals, the 
length of the CGG repeats vary between 6-54, whereas the premutation carriers contain 55-200 repeats 
(168). The premutation carriers are at increased risk of developing a condition known as fragile X-
associated tremor/ataxia syndrome (FXTAS). FXTAS is more common in males than females. Females 
are at risk of fragile X-associated primary ovarian insufficiency (FXPOI) (169, 170). The FXTAS and 
FXPOI symptoms are caused by increased transcription of the FMR1 gene and slightly reduced 
expression of FMRP (171). In both full mutation and premutation individuals, the severity of the 
phenotype depends on the number of CGG repeats (172). The repeat number has the tendency to increase 
every generation (173).  
 
5.9.2 FMRP 
FMRP is an RNA binding protein ubiquitously expressed in all mammalian tissues, predominately in 
brain and testis (20). In the brain, FMRP is mainly expressed in the cell body and dendrites of neurons 
(20, 174, 175) and also in axonal compartments (176, 177). Initially, the FMRP expression was shown 
to be restricted to neurons, however, later confirmed in astrocytes, oligodendrocytes and microglia of 
developing and adult mouse brain (178). FMRP is associated with the ribosomes via RNA in the 
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cytoplasm (174). FMRP contains functional nuclear localization and export signals indicating that FMRP 
shuttles between nucleocytoplasmic space (179, 180). In the nucleus, FMRP interacts with its 
homologous proteins fragile X related proteins 1 and 2, other proteins, and RNA/mRNA to form a 
ribonucleocomplex, which is likely involved in mRNA export from the nucleus to the cytoplasm (13). In 
the cytoplasm, FMRP along with its nuclear partners interacts with cytoplasmic proteins, such as FMRP-
interacting protein 1 and 2 and regulates protein synthesis at synapses (13). FMRP selectively binds to 
as much as 4% of the total mRNAs in the mammalian brain (181). It contains four RNA-binding motifs: 
three KH domains (KH0, KH1, and KH2) and an arginine-glycine-rich box that mediates mRNA 
transport, stability, and regulation of translation (181, 182). FMRP represses the translation of mRNAs 
that are involved in neuronal and synaptic transmission such as NMDAR subunits, mGluR5, postsynaptic 
density 93 & 95, Shank 1-3, neuroligins 1-3 (183). Some of these mRNAs are identified as candidate 
genes for autism (184). In the absence of FMRP, translational repression of target mRNAs fails, leading 
to alterations in synaptic plasticity and dendritic spine dynamics, which are thought to underlie the 
clinical manifestations of FXS (185).  
  
5.9.3 Fmr1-KO mouse model 
Significant advancements have been made in fragile X research since the generation of the mouse Fmr1 
gene knockout model. Fmr1-knockout (Fmr1-KO) mice are the most widely used murine model for FXS 
and were generated by inserting a neomycin cassette in exon 5 of the Fmr1 gene (186). The murine 
FMRP shows 97% amino acid homology to its human counterpart (187). Similar to humans, the life 
expectancy of Fmr1-KO mice is normal. Although the human FXS condition results from expanded CGG 
repeats, both human and mouse models are functionally identical with no FMRP production. Indeed, the 
Fmr1-KO model recapitulates many phenotypes observed in human FXS patients. They show similar 
morphological abnormalities in synapse structure, altered synapse function and an abundance of 
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immature dendritic spines (188). In addition, Fmr1-KO show learning deficits, hyperactivity and 
increased risk of seizures (186, 189). FMRP deficiency leads to the excessive synthesis of microtubule-
associated protein 1B (MAP1B), Ca2+/calmodulin-dependent protein kinase II (CaMKII), and the 
activity-regulated cytoskeleton-associated protein (Arc) in synaptoneurosomes (SNS) of Fmr1-KO mice 
(190), whose function is linked with synaptic plasticity. Subsequently, excessive translation of mRNAs 
is shown in cortical SNS (191), suggesting that absence of FMRP results in exaggerated protein synthesis 
at synapses.  
 
5.9.4 FMRP and glutamatergic signaling 
Extensive preclinical evidence on animal models of FXS has demonstrated that aberrant signaling via 
group 1 mGluRs has important consequences on the mechanisms involved in dysregulated synaptic 
plasticity in the absence of FMRP. Group 1 mGluRs include mGluR5 that is highly expressed in cortex, 
striatum, and CA1 and CA3 regions of the hippocampus and mGluR1 mainly expressed in the 
cerebellum, thalamus, and CA3 region of the hippocampus (192). Weiler et al. first demonstrated the 
connection between FMRP and mGluR pathways; they observed that activation of group 1 mGluRs by 
DHPG increased protein synthesis, including FMRP, in SNS (175). Later, Huber et al. showed that the 
absence of FMRP leads to increased mGluR-dependent protein synthesis and altered synaptic plasticity, 
including enhanced LTD in the postnatal and adult brain of Fmr1-KO mice (14). They also showed that 
NMDA-dependent LTD is normal in Fmr1-KO mice suggesting that the phenotype is linked exclusively 
to mGluR-dependent LTD (14, 193, 194). This led to the mGluR theory of FXS (15), which postulates 
that the absence of FMRP results in overactive glutamatergic signaling via mGluR5. The activation of 
group I mGluRs stimulates protein synthesis responsible for the internalization of synaptic AMPARs and 
NMDARs (195, 196). Thus, in the normal brain, activation of mGluRs increases FMRP synthesis, which 
then negatively regulates the protein translation involved in AMPAR internalization during LTD (13). 
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In Fmr1-KO mice, the absence of FMRP increases translation of LTD proteins leading to aberrant 
glutamate receptors trafficking and consequently causing changes in synaptic plasticity (13, 197-199). 
Unlike normal mGluR-LTD, the Fmr1-KO mGluR-LTD does not require new protein synthesis because 
of basally elevated proteins levels in the absence of FMRP (200, 201).  
 
Proteins regulating AMPAR endocytosis such as MAP1B, Arc, striatal-enriched protein tyrosine 
phosphatase (STEP) and amyloid precursor protein (APP) are upregulated in the brain of Fmr1-KO mice 
(190, 198, 202). AMPARs surface expression is decreased during hippocampal mGluR-LTD in Fmr1-
KO mice (162, 200, 203) in agreement with the increased expression of AMPAR endocytosis proteins. 
Furthermore, in Fmr1-KO mice, GluA1 is decreased in the cortical synapses (204), synapse membrane 
(205, 206) and hippocampal neurons (207). The GluA1 and GluA2/3 levels are reduced in the SNS 
fractions of one-week-old Fmr1-KO mice, and at later developmental stage only GluA1 is reduced in 
SNS, while GluA2/3 and GluNR2B levels are reduced in cortical homogenates (208). Both protein and 
mRNA expression levels of GluA1 are decreased in the cerebral cortex, hippocampus and amygdala 
synaptosome extracts of Fmr1-KO mice (204, 209). In addition to the changes in AMPAR subunits 
expression, abnormal NMDAR expression patterns are observed in FXS. The GluNR1, NR2A, and 
NR2B levels are significantly reduced in homogenates and SNS fractions extracted from the prefrontal 
cortex (210) and in DG (211) of Fmr1-KO mice. Moreover, a significantly lower AMPA/NMDA ratio 
is observed just before the closure of the normal critical period in Fmr1-KO mice (212). In another Fmr1-
KO2 mouse model, Pilpel et al. also reported lower AMPA/NMDA ratio at postnatal day 14, which is 
related to the upregulation of NMDAR component paralleled with downregulation of AMPAR 
component (213), suggesting that the AMPAR/NMDAR function is dysregulated in Fmr1-KO mice.  
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Genetic reduction of 50% mGluR5 signaling in Fmr1-KO mice corrects dendritic spine density, ocular 
dominance plasticity, inhibitory avoidance extinction, audiogenic seizures, body weight loss, and 
excessive protein synthesis (214). Complete Grm5 knockout mice show impaired brain function (215); 
therefore it is vital to study heterozygous mice (Fmr1-/y; Grm5+/-) with 50% reduction in mGluR5 
expression (214). Following the identification of a potent and selective, noncompetitive antagonist MPEP 
(216, 217), several groups reported the beneficial effects of antagonizing mGluR5 in FXS. In Fmr1-KO 
mice, MPEP treatment resulted in suppression of audiogenic seizure phenotype (218, 219), reduction in 
repetitive-like behavior (219, 220), rescued prepulse inhibition (PPI) (221), and normalized the increased 
density of immature spines and excessive protein synthesis (214, 221). MPEP administration in 2-week-
old Fmr1-KO mice rescued the immature morphology of pyramidal neurons in the somatosensory cortex 
(222). Other mGluR5 antagonists, such as fenobam or mavoglurant, are also shown to have positive 
effects on FXS phenotype (223-225). These findings support the mGluR theory by showing that either 
by genetically reducing or by pharmacologically antagonizing mGluR5 signaling, the main phenotype of 
FXS can be completely rescued.  
 
5.9.5 FMRP and neural progenitors 
FMRP is widely expressed during embryonic development in both mouse and human (18-20), 
particularly in the regions where proliferating NPCs and newly born neurons are found. In normal mice, 
FMRP expression is highly detected at the end of the first postnatal week, and decline gradually thereafter 
(226, 227), indicating that FMRP plays a crucial role in early development. Altered NPCs proliferation 
and differentiation are reported in FXS. However, the biology of NPCs in FXS is not well characterized 
as very few groups have focused on studying early neuronal development. The studies of mouse NPC 
proliferation showed variations, which may depend on different methodologies, brain regions and 
developmental stages used. Neural colony-forming cell assay (228) has shown that the proliferation of 
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primary progenitors did not differ in neurospheres derived from the embryonic brains of Fmr1-KO and 
WT mice (21, 229). Similarly, no alterations have been reported in NPC proliferation in DG of Fmr1-
KO mice (25), and in human FXS fetal cortex derived NPCs (230). However, the proliferation of 
secondary progenitors has been shown to be increased both in vitro and in vivo (21, 22). Increased 
neuronal differentiation and decreased astrocyte differentiation is observed in NPCs derived from mouse 
embryonic brain, human fetus, and in DG of Fmr1-KO mice (21, 25). In contrast, increased astrocyte 
differentiation and decreased neuronal differentiation is observed both in vitro and in vivo of DG of 8-10 
week-old mice and NPCs derived from human embryonic stem cells (ESCs) (23, 24, 231). Callan et al. 
showed excessive proliferation of NPCs and accumulation of an increased number of neurons in dFmr1 
mutant brain (232). Furthermore, lack of FMRP is shown to suppress transition of RG cells into IP cells 
via an actin-dependent mechanism (233), in line with the reduced production of RG (21, 25, 44). Another 
line of research shows that neurons generated from NPCs of DG of adult Fmr1-KO mice display impaired 
NMDAR-dependent synaptic plasticity (211). However, neurons in the CA1 region of the hippocampus 
showed no alterations in NMDAR-dependent synaptic plasticity (211). NMDAR-dependent activity is 
inversely correlated with NPC proliferation in the DG, indicating that impaired NMDAR-dependent 
activity might also lead to NPC dysregulation (234). Altogether, these results highlight the importance 
of FMRP in NPC maintenance and fate determination in both the developing and adult brain. 
 
Recently, many research groups have generated NPCs from FXS hiPSCs to study the mechanisms 
involved in altered neuronal function, to identify the compounds that can reactivate a silent FMR1 locus, 
and to restore FMR1 gene expression. Gene expression and DNA methylation profiling studies 
demonstrated that NPCs generated from FXS hiPSCs exhibit alterations in expression of genes that are 
responsible for neurodevelopment, migration, and axon guidance (235). Few other groups succeeded in 
deleting the elongated CGG repeat in FXS hiPSC and undifferentiated cells using CRISPR/Cas9 genome 
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editing method (236-238). The deletion of CGG repeats resulted in promoter demethylation and 
restoration of FMR1 gene expression in FXS hiPSCs and sustained throughout the neural rosette 
formation and in mature neurons (236-238). Bar-Nur et al. showed that DNA methyltransferase inhibitor 
5-Azacytidine reactivated FMR1 gene expression in FXS hiPSC derived neurons (239). Accordingly, 
high-throughput screening of FXS hiPSC derived NPCs revealed 5-Aza-2-deoxycytidine and 5-
Azacytidine as positive hits (238). All these findings emphasize the importance of studying early 
developmental time stages, where FMRP is highly expressed, to understand the contribution of NPCs in 
altered neuronal and circuit excitability observed in FXS. The hiPSC studies reported in FXS are 
summarized in table 2.  
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6. Aims of the study  
The overarching aim of my doctoral thesis was to identify novel targets for pharmacological intervention 
in FXS. The study mainly focused on investigating the involvement of glutamate signaling in early 
neuronal differentiation and migration of NPCs lacking FMRP. The findings obtained with NPCs derived 
from FXS hiPSC lines were compared with those derived from Fmr1-KO embryonic mouse brain. 
 
The specific aims of the study were as follows: 
I. To understand the role of tPA in the differentiation, migration and activity-dependent 
responses of FMRP-deficient NPCs 
II. To functionally characterize differentiation of glutamate-responsive cell populations and to 
identify mGluR5-mediated abnormalities during differentiation of human and mouse FMRP-
deficient NPCs 
III. To investigate the mechanisms involved in enhanced differentiation of cells with Ca2+-
permeable AMPARs in human and mouse FMRP-deficient NPCs 
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7. Materials and Methods 
7.1 Mouse model (I-III) 
7.1.1 Fmr1-knockout mice 
Fmr1-KO (B6.129P2-Fmr1tml/Cgr/J, Jackson Laboratory) and wild-type (WT) mice were maintained in 
C57BL/6J genetic background (I-III). Fmr1-KO mice were generated (186) and genotyped by tail-PCR 
as described previously (21). Female Fmr1-/+ mice were crossed with male WT mice and embryos with 
Fmr1-KO, and WT genotypes were used in the study. All animals were group-housed by the guidelines 
of the National Institute of Health at the Animal Centre, University of Helsinki. The experiments were 
accomplished in accordance with the European Economic Community Council Directive and protocols 
were approved by the Experimental Animal Ethical Committee of the National Laboratory Animal 
Center, Finland.  
 
For studies of early cortical neurogenesis (II), heterozygous female Fmr1-/+ mice carrying embryos 
received intraperitoneal (i.p.) injections of 5-Bromo-2-deoxyuridine (BrdU; 50 mg/kg) at embryonic day 
14 (E 14). Two heterozygous pregnant female Fmr1-/+ mice received i.p. injections of MPEP (10 mg/kg) 
along with BrdU injections.   
 
7.1.2 Brain tissue 
Pregnant mice were sacrificed by cervical dislocation and pups by decapitation after being anesthetized 
with CO2. Cell cultures were prepared from the mouse brain tissues at E14 (I-III). The embryonic day 17 
(E17), postnatal day 7 (P7), and adult brains were collected for paraffin sectioning (I,II). Freshly collected 
brains were fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde (PFA) at +40C 
overnight (O/N) followed by dehydration with ethanol series: 70% for 2 h, 96% for 2 h, and 100% at 
+40C O/N. Brains were washed with xylene for 2 h and immersed in paraffin at +600C O/N. On the 
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following day, paraffin molded brains were sectioned into 20 μm coronial sections onto cover glasses 
using a MICROM HM 355 microtome (Thermo Fisher Scientific).  
 
7.1.3 Generation and culturing of neural progenitors 
Cortical NPCs were used to examine intracellular calcium ([Ca2+]i) responses, cell motility, whole-cell 
currents, protein expression, and mRNA expression levels (I-III). NPCs were propagated from the wall 
of lateral ventricles of WT and Fmr1-KO mice as previously described (250). The dissected brain tissue 
(E14) was dissociated in (mg/ml) 0.2 kynurenic acid, 0.7 hyaluronidase, and 1.33 trypsin, in Hank’s 
balanced salt solution (HBSS) containing 2 mM glucose at +370C for 30 min. After titration, the cells 
were centrifuged at 200 X g for 5 min, and the pellet was resuspended in HBSS containing 0.9 M sucrose 
and centrifuged at 750 X g for 10 min. Thereafter, cells were resuspended in Earl’s balanced salt solution 
(EBSS) and centrifuged through a gradient of 12 ml EBSS containing 4% bovine serum albumin (BSA) 
at 200 X g for 7 min. The cell pellet was resuspended in Dulbecco’s modified Eagle’s medium nutrient 
mixture F-12 (DMEM/F-12) containing B27 supplement, L-glutamine (2 mM), HEPES (15 mM), 
penicillin (100 U/ml), and streptomycin (100 U/ml) and cultured in the presence of bFGF (10 ng/ml) and 
EGF (20 ng/ml). Cells were grown as free-floating aggregates known as neurospheres (46) in a 5% CO2-
humidified incubator at +370C. The culture medium was refreshed (50% of the medium) twice and 
growth factors were added thrice per week. The neurospheres were passaged by manual trituration 
approximately once a week, and all the experiments were performed on neurospheres between passages 
3 and 10. 
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7.2 Human model (II,III) 
7.2.1 FXS induced pluripotent stem cells 
Seven hiPSC lines were used in the study: HEL100.1, HEL100.2, HEL70.3, and HEL69.5 (full mutation; 
FXS), and HEL46.11, HEL23.3, and HEL11.4 (control) (II,III). With informed consent, human samples 
were collected from boys diagnosed with FXS (age range: 6-13 years) and from healthy individuals (age 
range: neonatal and 83). hiPSC lines were reprogrammed at the Biomedicum Stem cell center (University 
of Helsinki) using CytoTune-iPS Sendai Reprogramming Kit. The hiPSCs were grown as monolayer 
cultures on Matrigel-coated plates in Essential 8 medium and maintained in a 5% CO2-humidified 
incubator at +370C. The culture medium was replaced every alternate day, and the cell colonies were 
passaged approximately once every 4-5 days with 0.5 mM EDTA in PBS. All iPSC lines used for 
generation of NPCs were between passages 15 and 40. 
 
7.2.2 Generation and culturing of neural progenitors 
Neural differentiation was induced as previously described (79). NPCs were generated from both control 
and FXS hiPSC lines and further used to examine [Ca2+]i responses, protein expression, mRNA 
expression levels, and transcriptional profile (II,III). hiPSC colonies were grown on low adherent plates 
in neuronal differentiation medium containing DMEM/F-12: Neurobasal (1:1), Glutamax (2 mM), B27 
and N2 supplement in the presence of bFGF (20 ng/ml). Under these conditions, the hiPSCs form free-
floating aggregates (neurospheres) in 2-4 days. After the first week, the culture medium was replaced 
completely, and growth factors were added every 2-3 days. Neurospheres were grown for 6-8 weeks and 
manually passaged approximately once a week, and all the experiments were performed on neurospheres 
between passages 6 and 8. 
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7.3 Neurosphere differentiation (I-III) 
For experiments, human (II,III) and mouse (I-III) neurospheres (average size 200-250 μm) were plated 
on poly-D-lysine/laminin and poly-DL-ornithine coated cover glasses in the absence of growth factors, 
respectively. Neurospheres were differentiated in the presence or absence of tPA blocker, MPEP, 
Philanthotoxin (PhTx), or Naspm trihydrochloride (Naspm) for the indicated periods of time. Growth 
factors were always added to the cells a day before experimentation and cell cultures were tested regularly 
to ensure that they were free from mycoplasma contamination. 
 
7.4 Calcium Imaging (I-III) 
Ca2+ imaging was performed (21) to analyze functional responses in human and mouse NPCs (I-III). 
Cells were stimulated with different glutamate receptor agonists/antagonists and changes in the [Ca2+]i 
levels were recorded. For experiments, cells were loaded with 4 μM fura-2 acetoxymethylester (fura-
2/AM; Ca2+ indicator) at +370C for 20 min in HEPES-buffered medium (in mM): 137 NaCl, 5 KCl, 0.44 
KH2PO4, 4.2 NaHCO3, 10 glucose, 2 CaCl2, and 0.5 MgCl2. Thereafter, coverslips were attached to a 
temperated perfusion chamber and cells were perfused continuously with an external solution at 2 ml/min 
at +370C. The fluorescence intensities were recorded after continuous excitation of the measured cells at 
340 nm and 380 nm using a 430 nm dichroic mirror and 510 nm barrier filter with an integrating charge-
coupled device camera (Olympus). An image (340/380 nm) was acquired every second. One neurosphere 
per coverslip (4-10 coverslips/group) was analyzed and [Ca2+]i rise in the soma of 40-100 cells derived 
from each neurosphere was measured. Cells were stimulated with agonists, and after recording the 
response, cells were washed with HBM to recover the basal [Ca2+]i levels. The data were analyzed using 
InCyt 4.5 software (Intracellular Imaging Inc.) or Cell R software (Olympus) and further processed with 
Origin 6.0 software (OriginLabCorp.). All agonists and antagonists are listed in table 3.  
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Table 3: Agonists/Antagonists used in the study  
Compound Agonist/Antagonist Manufacturer Final concentration 
(μM) 
Publication 
DHPG Group I mGluR agonist Tocris  10 II,III 
Kainic acid Kainate/AMPAR agonist Tocris 50 II,III 
NMDA NMDAR agonist Tocris 50 II,III 
Glycine NMDAR potentiator Tocris 10 II,III 
AMPA AMPAR agonist Tocris 50 III 
Naspm  AMPAR antagonist Tocris 10 III 
PhTX Kainate/AMPAR antagonist Tocris 10 III 
 
AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; DHPG, (S)-3,5 
dihydroxyphenylglycine; Naspm, Naspm trihydrochloride; NMDA, N-methyl-D-aspartate; PhTx, 
philanthotoxin.  
 
7.5 Time-lapse live imaging (I,II) 
The Cell-IQ live imaging system (Chip-Man Technologies) was used to monitor cellular movement 
during early differentiation of mouse NPCs (I,II). The Cell-IQ system is a cell-culturing instrument 
combined with phase contrast microscopy, automation, and environmental control. The system contains 
an integrated incubator, precision movement stages (x, y-axes: ± 1μm; z-axis:  ±0.4 μm), two gas flow 
controllers, and an automated optics module fully controlled through machine vision-based firmware and 
analysis software. Cell movement was monitored continuously during first 24 h period in two 6-well 
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plates attached to an integrated plate holder in the incubator. Image analysis was performed using ImageJ 
or onboard analyzer software. 
 
7.6 Immunostaining (I-III) 
7.6.1 Immunohistochemistry 
Paraffin sections (I,II) were deparaffinized in xylene and rehydrated in ethanol series and water. Sections 
were subjected to antigen retrieval by boiling in 10 mM citrate buffer for 15 min and blocked with 0.5% 
Triton X-100 and 20% normal goat serum (NGS) in PBS at room temperature (RT) for 1 h. Thereafter, 
sections were incubated with primary antibodies at +40C O/N followed by incubation with secondary 
antibodies at RT for 1 h. The cell nuclei were counterstained with 4’,6-Diamidino-2-Phenylindole 
(DAPI). The fluorescent images were obtained with AxioPLAN 2 imaging microscope, and LSM Pascal 
laser scanning confocal microscope (both from Zeiss) and processed using ImageJ software. All primary 
and secondary antibodies are listed in table 4 and 5.  
 
7.6.2 Immunocytochemistry  
Differentiated human and mouse NPCs (I-III) were fixed with 4% PFA at RT for 10 min. Cells were 
permeabilized and blocked using 10% NGS and 1% BSA in PBS containing 0.1% Triton X-100 at RT 
for 45 min. Thereafter, cells were incubated with primary antibodies at +40C O/N followed by incubation 
with secondary antibodies at RT for 1 h. Finally, cells were washed with PBS and counterstained with 
Vectashield mounting medium containing DAPI. The fluorescent images were obtained with AxioImager 
(Zeiss) and processed using ImageJ software (ImageJ developers). All primary and secondary antibodies 
are listed in table 4 and 5. 
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Table 4: Primary antibodies used in the study 
 
 
ICC, Immunocytochemistry; IHC, Immunohistochemistry; WB, Western Blotting. 
*Dilution used according to manufacturer’s instructions. 
 
Antibody Host Manufacturer Dilution Publication Method 
Anti-PLAT Rabbit Proteintech 1:50 I IHC 
Anti-PAI-1 Rabbit Abcam 1:500 I IHC 
Anti-GFAP Chicken Abcam 1:1000 I IHC 
Anti-TrkB Rabbit Santa Cruz Biotechnology 1:150 I IHC 
Anti-tPA Mouse American Diagnostica 10mg/ml I ICC 
Anti-GFAP Rabbit Millipore 1:1000 I,II ICC 
Anti-BLBP Rabbit Millipore 1:750 I,II ICC 
Anti-DCX Guinea pig Millipore 1:100 I,II ICC 
Anti-MAP2 Mouse Millipore 1:500 I,II,III ICC 
Anti-Tbr2 Rabbit Chemicon 1:2000 II IHC 
Anti-BrdU Mouse Amersham * II IHC 
Anti-mGluR5 Rabbit Millipore 1:50 II ICC 
Anti-FMRP Rabbit Abcam 1:500 II WB 
Anti-TRA1-60 Mouse Thermo Fisher 1:500 II,III ICC 
Anti-OCT4 Rabbit Cell signalling 1:500 II,III ICC 
Anti-SSEA3 Rat Millipore 1:100 II,III ICC 
Anti-GluA2 Mouse Millipore 1:100 III ICC 
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Table 5: Secondary antibodies used in the study  
Antibody Species reactivity Manufacturer Dilution Publication Method 
Alexa Fluor 568 Rabbit Invitrogen 1:500-1000 I ICC 
Alexa Fluor 488 Chicken Invitrogen 1:500-1000 I IHC,ICC 
Alexa Fluor 568 Guinea pig Invitrogen 1:5000 I,II ICC 
Alexa Fluor 488 Rabbit Invitrogen 1:2000 I,II,III IHC,ICC 
Alexa Fluor 488 Mouse Life 
technologies 
1:500 I,II,III ICC 
HRP conjugate Rabbit GE Healthcare 1:10000 II WB 
Alexa Fluor 488 Rat Life 
technologies 
1:500 II,III ICC 
Alexa Fluor 568 Mouse Invitrogen 1:5000 II,III ICC 
 
ICC, Immunocytochemistry; IHC, Immunohistochemistry; WB, Western Blotting. 
 
7.7 Quantitative PCR (II,III) 
Gene expression levels were quantified in human and mouse NPCs, and in mouse prefrontal cortex, using 
qPCR (II,III). Total RNA was extracted with the Norgen’s RNA purification kit followed by cDNA 
synthesis (1 μg of total RNA) with iScriptTM or Transcriptor First Strand cDNA synthesis kit. qPCR 
was performed with SYBR Green I kit using Light Cycler 480 II Real-Time PCR system (Roche). For 
miRNA assays, cDNA was prepared from 100 ng of total RNA with TaqMan microRNA RT kit followed 
by qPCR with TaqMan universal Mmix II. All samples were run in triplicates and data were analyzed 
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using second derivative max method determining the threshold cycle (Ct) (251). GAPDH and miR-191 
were used as internal controls. PCR Primers are listed in table 6. 
 
Table 6: PCR primers used in the study 
Gene Forward primer Reverse primer 
FMR1 5'-GAAAACAACTGGCAGCCTGATAG-3' 5'-CATTTGCTCTGGAATACACCTC 
AAC-3' 
GRIA1 5'-CCCTGAGAGGTCCCGTAAAC-3' 5'-ACTTCCGGAGTCCTTGCTTC-3' 
GAPDH 5'-TGTTCCAATATGATTCCACCC-3' 5'-CTTCTCCATGGTGCGTGAAGA-3' 
mGluR5 5'-AGCGCCTTCACAACCTCTAC-3' 5'-CCTGTCGCTGTGCATCCT-3' 
Gria1 5'-GGGGTCCGCCCTGAGAAATCCA-3' 5'-TGGAGTCACCTCCCCCGCTG-3' 
Gria2 5'-CGGGGGAGGTGATTCCAAGGAAAAG-3' 5'-CCAAACCAAGGCCCCCGACA-3' 
Gapdh 5'-AACGACCCCTTCATTGAC-3' 5'-TCCACGACATACTCAGCAC-3' 
 
microRNA Primer  miRBase Accession number 
miR-181a-5p AACAUUCAACGCUGUCGGUGAGU MI0000289 
miR-181a-3p ACCAUCGACCGUUGAUUGUACC MI0000289 
miR-191-5p CAACGGAAUCCCAAAAGCAGCUG MI0000465 
 
7.8 Western Blotting (II) 
The FMRP expression in hiPSCs was measured using Western blotting. Cells were lysed in ice-cold 
RIPA buffer and supplemented with protease and phosphatase cocktail. An equal amount (90 μg) of 
protein was separated by polyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane, 
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and blocked with 5% nonfat dry milk at RT for 1 h. Thereafter, the membrane was incubated with primary 
antibody (Table 4) at +40C O/N followed by incubation with horse peroxidase-conjugated secondary 
antibody (Table 5) at RT for 1 h. The immunoreactive FMRP was detected using G: BOX Chemi XX6 
imaging system (Syngene).   
 
7.9 Patch clamp recordings (III) 
Patch clamp recordings were performed in mouse NPCs to measure whole-cell currents using Axopatch 
1B patch clamp amplifier (Molecular devices). Coverslips with cells were placed onto the microscope 
and perfused continuously with external recording solution (in mM): 150 NaCl, 2.5 KCl, 10 glucose, 10 
HEPES, 2.5 CaCl2, and 1 MgCl2. All agonists/antagonists were diluted in the recording solution and 
applied to the cells through the piezo-driven applicator (Siskiyou Corporation). The recording 
micropipettes (3-4 MΩ) were filled with internal solution (in mM): 100 N-methyl-D-glucamine, 100 
CH3SO3H, 40 CsF, 10 HEPES, 10 MgCl2, and 5 EGTA. For I-V curve recordings, spermine was added 
to the internal solution. Data were low-pass filtered at 1 kHz and acquired at 5 kHz, and analyzed using 
Clampfit 10.2 software (Molecular devices) and Prism 4.02 software (GraphPad). Glutamate receptor 
agonists/antagonists used in the study included: 1 mM L-glutamate; 100 μM Cyclothiazide; 10 μM 
NBQX; 10 μM Naspm. 
 
7.10 Transcriptional profiling (III) 
Gene expression profiling was performed with human NPCs using Affymetrix Human Clariom D array 
(Thermo Fisher Scientific). Biotinylated cRNA was prepared from 100 ng of total RNA using the 
GeneChip WT plus reagent kit. Following fragmentation, 5.2 μg of cRNA was hybridized to Affymetrix 
Human Clariom D arrays and scanned using a Hewlett-Packard GeneChip Scanner 3000. The CEL files 
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were processed and normalized using Signal Space Transformation – Robust Multichip analysis. 
Affymetrix Expression Console software was used to analyze the processed gene data files. 
 
7.11 Statistical analysis (I-III) 
The statistical comparisons were carried out using two-sided Student’s unpaired t-test (I-III), Fisher’s 
exact test (II,III), One-way ANOVA followed by post hoc Tukey/Bonferroni test (I,III), and Mann-
Whitney test (III). Levene’s and Shapiro-Wilk test was used to check the homogeneity of variances and 
normality of the data, respectively. All statistical tests were performed using IBM SPSS analysis software 
(IBM Analytics). P value < 0.05 was considered statistically significant. 
 
7.12 Experimental setup 
 
Figure 2: The experimental setup used to study human and mouse cellular models. iPSCs, induced 
pluripotent stem cells. 
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8. Results 
8.1 Tissue plasminogen activator contributes to alterations of neuronal migration and activity-
dependent responses in fragile X mice (I) 
8.1.1 tPA expression in NPCs and in brain of Fmr1-KO mice 
We compared the tPA expression in embryonic cortical NPCs, in developing and mature brain of Fmr1-
KO mice to that in WT controls. A significant increase was seen in the number of tPA-immunoreactive 
cells in FMRP-deficient neurospheres at day 7 and 14 of differentiation (Article I: Figure 1A,B). The 
tPA-positive cells mainly co-expressed GFAP in both WT and Fmr1-KO cells (Article I: Figure 1B,D), 
however, tPA expression was not seen in MAP2-positive cells (Article I: Figure 1C). Furthermore, an 
abnormal expression pattern was observed for tPA in the developing brain of Fmr1-KO mice (Article I: 
Figure 4A). The proportion of tPA-immunoreactive cells was increased in cortical layers I-III (1.8 fold) 
and decreased in layers IV-VI (0.7 fold) at P7 (Article I: Figure 4C,D). The number of tPA-positive cells 
was increased (3.2 fold) paralleled with reduction of PA1-1 expressing cells (0.7 fold) in the DG of Fmr1-
KO mice (Article I: Figure 4E,F). Also, the tPA expression was significantly increased in somatosensory 
cortex, visual cortex, and DG of the adult brain of Fmr1-KO mice (Article I: Figure 5A-D). Likewise in 
FMRP-deficient neurospheres, tPA-immunoreactive cells colocalized with GFAP in both cortex and 
hippocampus of Fmr1-KO mice (Article I: Figure 5C,D).  
 
8.1.2 Effects of tPA on migration and intracellular calcium responses to depolarization in mouse NPCs 
lacking FMRP 
In the neurosphere model, cells migrating out of the cluster initially display RG morphology followed 
by maturing neuron-like cells (76, 77). The morphology of the cells correlated with immunocytochemical 
stainings showing that the majority of RG cells are immunopositive to BLBP, and neuron-like cells are 
immunopositive to DCX (Article I: Figure 2B). Using time-lapse live imaging, neuron-like cells lacking 
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FMRP were observed to migrate longer distances from the edge of the neurosphere after 24 h of 
differentiation (Article I: Figure 2A). Treatment of FMRP-deficient cells with tPA-neutralizing antibody 
normalized the distance migrated by neuron-like cells to WT levels (Article I: Figure 2A). Similarly, 
treatment with tPA blocker normalized the distance migrated by DCX-immunoreactive FMRP-deficient 
NPCs (Article I: Figure 2B,C). Besides, blocking tPA activity rescued the distance traveled by RG and 
the velocity of the interkinetic nuclear migration (INM) of FMRP-deficient RG (Article I: Figure 2D-
F). Furthermore, the involvement of tPA on [Ca2+]i responses to depolarization during early NPC 
differentiation is reported. To understand the possible correlation between distance migrated and 
functional responses the whole migration was divided into three zones (21 μm/each zone, from the edge 
of the neurosphere) (Article I: Figure 3A). Depolarization with 17 and 75 mM extracellular potassium 
([K+]e) caused changes in [Ca2+]i levels in most cells migrating out of the neurosphere in both FMRP-
deficient and WT neurospheres. The amplitude of response to depolarization with 17 and 75 mM [K+]e 
was enhanced in the outer migration zones of FMRP-deficient cells (Article I: Figure 3C,D). Treatment 
with tPA-neutralizing antibody lowered the Ca2+ responses only in FMRP-deficient NPCs (Article I: 
Figure 3E). In summary, the results implicate a vital contribution of glial cells to altered neuronal 
differentiation in FXS (252) and indicate the involvement of tPA-mediated mechanisms in the aberrant 
migration and functional changes of FMRP-deficient RG. 
 
8.2 Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to 
NMDA-responsive cells in Fragile X syndrome (II) 
8.2.1 Functional characterization of glutamate-responsive NPCs and MPEP effects on mouse FMRP-
deficient cells  
To improve understanding of altered mGluR signaling in FXS (14, 15), mGluR5-mediated changes were 
studied during early differentiation of NPCs derived from Fmr1-KO mice. Consistent with the spatial 
distribution of cell populations observed with immunostainings, the [Ca2+]i responses to DHPG 
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dominated in the cells closer to the neurosphere. After longer differentiation, [Ca2+]i responses to DHPG 
decreased, and responses to activation of iGluRs (kainate, AMPA, NMDA) increased towards the outer 
migration zone.  
 
The [Ca2+]i responses to activation of glutamate receptor agonists were functionally characterized in 
Fmr1-KO neurospheres and responses were compared with those in WT controls. In the absence of 
extracellular Ca2+, DHPG caused only a transient rise in [Ca2+]i, whereas a sustained Ca2+ response was 
observed in the presence of extracellular Ca2+ (Article II: Figure 1B). At day 7 of differentiation, the 
proportion of DHPG-responsive cells remained unaltered before and after treatment with MPEP (a 
specific mGluR5 antagonist) between Fmr1-KO and WT neurospheres (Article II: Figure 1C). To 
understand the distribution of DHPG-responsive cells, the migration area was divided into three zones 
(Article II: Figure 1D) (as described in study I). The proportion of DHPG-responsive cells was increased 
in zone 1 and reduced in zone 3 of FMRP-deficient cells (Article II: Figure 1E). MPEP treatment reduced 
the cell population in zone 2 and normalized in zone 3 (Article II: Figure 1D), without changes in the 
total DHPG-responsive cell population. Based on [Ca2+]i responses to mGluR and iGluRs activation, the 
differentiating NPCs were distinguished into three subpopulations (figure 3). In the type 1 subpopulation, 
the majority of cells showed a robust response to activation of mGluR and minor/no response to iGluRs 
(Article II: Figure 1F). The type 2 cell population showed a substantial response to activation of both 
mGluR and iGluRs (Article II: Figure 1H), and type 3 displayed a prominent response to the activation 
of iGluRs and no response to mGluR. The proportion of type 1 (Article II: Figure 1G) and type 3 
subpopulations of cells did not alter between WT and FMRP-deficient NPCs, even after MPEP treatment. 
However, a significant increase was seen in the type 2 cell population in FMRP-deficient cells, and MPEP 
treatment normalized the abnormal differentiation of the subpopulation (Article II: Figure 1I). In 
addition, the type 2 cell population was accumulated in zone 2 and displayed unipolar morphology 
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(Article II: Figure 1J,K). Treatment with MPEP normalized the accumulation and reduced the number 
of cells with unipolar morphology in FMRP-deficient cells (Article II: Figure 1J,K). In agreement with 
the enhanced differentiation of FMRP-deficient glutamate-responsive cells, a significant increase was 
observed in the magnitude of DHPG responses in all three zones of migration area of FMRP-deficient 
NPCs (Article II: Figure 2A). 
 
            Type 1 subpopulation                       Type 2 subpopulation          Type 3 subpopulation 
 
Figure 3: Neural progenitor subpopulations based on their responses to activation of glutamate receptors. 
DHPG, (S)-3,5-dihydroxyphenylglycine; KA, kainic acid; NMDA, N-methyl-D-aspartate. 
 
8.2.2 Effects of MPEP on motility and morphology of differentiating NPCs, and on cortical neurogenesis 
of Fmr1-KO mice  
We next examined the effects of MPEP on motility pattern and morphology of NPCs during early 
differentiation. Using time-lapse live imaging, the freely moving neuron-like cells were monitored in the 
outer border of migration area during the first 24 h of differentiation. The motility pattern was analyzed 
by the dividing the cell movement into periods of stalling (movement ˂ 30μm/h) and surges (movement 
˃ 30μm/h) in WT and Fmr1-KO neurospheres without and with MPEP treatment (Article II: Figure 4A-
D). The motility pattern (surges/stalling), mean velocity, and the distance traveled by neuron-like cells 
were increased in FMRP-deficient neurospheres (Article II: Figure 4E-G). MPEP treatment normalized 
the altered pattern and migration in only Fmr1-KO NPCs (Article II: Figure 4E-G). Furthermore, 
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treatment with MPEP increased the neurite length of MAP2-positive cells and rescued the number of 
multipolar GFAP-positive cells in FMRP-deficient neurospheres (Article II: Figure 5A-D). 
Administration of MPEP to E14 Fmr1-KO mice triggered a significant reduction in the number of Tbr2- 
but not BrdU-positive cells at E17 (Article II: Figure 6A-C). Tbr2 is expressed in VZ/SVZ of the 
neocortex during glutamatergic cortical neurogenesis (253). These results suggest that MPEP possibly 
corrects the aberrant neurogenesis in Fmr1-KO mice by reducing the increased differentiation of the 
glutamatergic cell population.  
 
8.2.3 Functional characterization of human iPSC-derived NPCs, and MPEP effects on FXS glutamate-
responsive cell populations  
Following the identification of mGluR5-mediated alterations in Fmr1-KO neurospheres, the same was 
examined in hiPSC-derived NPCs. Three controls and four FXS hiPSC lines were used in the study. All 
cell lines expressed pluripotency markers and FXS cell lines did not express FMR1 and FMRP (Article 
II: Figure S1). Most cells migrating out of the differentiating human neurosphere showed 
immunopositivity to MAP2 at day 1 of differentiation (Article II: Figure 3A) indicating that the cells 
were committed to the neuronal fate. In line with the enhanced differentiation, an increase in a DHPG-
responsive cell population was observed, coincident with an increased magnitude of responses to DHPG 
in FXS NPCs at day 7 of differentiation (Article II: Figure 3C,I). Similarly, the type 2 and type 3 cell 
population were more abundant in FXS NPCs (Article II: Figure 3D,E). Furthermore, both [Ca2+]i 
responses and the proportion of cells responding to activation of iGluRs were increased in FXS NPCs 
(Article II: Figure 3F,G,J,K). 
 
Unlike in mouse neurospheres, MPEP treatment further increased the DHPG-responsive and type 2 cell 
population in human FXS cells (Article II: Figure 3C,D). However, the type 3 cell population was 
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normalized after MPEP treatment (Article II: Figure 3E), which was almost negligible in mouse NPCs. 
MPEP treatment also normalized the FXS-specific increase in NMDA-responsive cells (Article II: 
Figure 3F), and reduced the amplitude of responses and cells responding to KA in FXS NPCs (Article 
II: Figure 3G,J). Altogether, these results strikingly demonstrate an FXS-specific increase in a 
subpopulation of NPCs and MPEP treatment showing cell-type specific effects on maturation of 
glutamate-responsive cells. 
 
8.3 Functional changes of AMPA responses in human induced pluripotent stem cell-derived neural 
progenitors in fragile X syndrome (III) 
8.3.1 Mechanisms involved in altered differentiation of CP-AMPAR expressing human FXS NPCs  
This study was set forth to investigate the molecular mechanisms involved in aberrant differentiation of 
glutamate-responsive cells in FMRP-deficient NPCs derived from hiPSCs. After differentiating 
neurospheres for 1 and 7 days, all cells in the migration area were sequentially challenged with NMDA, 
KA, and DHPG (Article III: Figure 1B). The proportion of glutamate-responsive cells was increased in 
FXS neurospheres at both day 1 and 7 of differentiation compared to controls (Article III: Figure 1C,D), 
in line with previous studies showing altered kinetics of FXS NPCs (45). Importantly, the [Ca2+]i 
responses and percentage of cells responding to KA were more abundant in FXS neurospheres (Article 
III: Figure 1F,G). KA is a potent AMPAR agonist that does not cause receptor desensitization (Article 
III: Figure 1E), whereas it exhibits transient effects on kainate receptors (254, 255). An identical 
abnormal increased response was seen when stimulated with specific AMPAR agonist in FXS NPCs 
(Article III: Figure 1H). A more detailed analysis revealed that the enhanced responses to KA were 
mainly detectable in the cell population that was responsive to either NMDA or DHPG (Article III: 
Figure 7B), suggesting a coordinate regulation of glutamate receptors in aberrant functional maturation 
of glutamate-mediated responses in FXS.  
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Next, the effects of Ca2+ permeable AMPAR (CP-AMPAR) blockers were tested on the increased Ca2+ 
permeability observed in FXS NPCs. PhTx, a blocker of CP-AMPARs, fully inhibited the sustained Ca2+ 
response to KA in 69 ± 5% FXS cells and 49 ± 4% control cells when applied through bath solution or 
treated prior (Article III: Figure 2A,B). Likewise, Naspm, a blocker of CP-AMPARs lacking GluA2 
subunit completely blocked the AMPA responses in 53.3 ± 3% FXS cells and 38.4 ± 7% control cells 
(Article III: Figure 2D,E). Since GluA2 subunit has been shown to regulate Ca2+ permeability (256, 
257), these results indicate that reduced GluA2 expression led to increased Ca2+ permeability in NPCs 
lacking FMRP (figure 4). Cells sensitive to CP-AMPAR blockers predominantly co-expressed NMDA 
receptors in FXS cells (Article III: Figure 2C,F), which correlated with enhanced differentiation of 
glutamate-responsive cells in FXS. The reduction of GluA2 protein expression in FXS neurospheres was 
confirmed using immunocytochemical analysis (Article III: Figure 5A).  Furthermore, the normal 
developmental regulation of GRIA1 transcript levels shown in WT NPCs (77, 111) was absent in FXS 
neurospheres (Article III: Figure 5C), suggesting aberrant maturation of AMPARs during early 
differentiation of FXS NPCs.  
 
Figure 4: Reduced GluA2-lacking AMPA receptors caused increased calcium permeability of human 
FXS neural progenitors.  
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To shed further light on the underlying mechanisms responsible for reduced GluA2 expression, 
transcriptome analysis was undertaken, showing that MIR-181A1 host gene expression was increased (P 
꞊ 0.018) in FXS NPCs. The non-coding MIR-181A1 host gene generates miR-181a and miR-181b 
microRNAs, which regulate GluA2 expression (258, 259). Particularly, miR-181a has been shown to 
have a direct interaction with GluA2 subunit and inhibits its activity posttranscriptionally (258, 260). 
Using qPCR, the mRNA expression of miR-181a was validated and the miR-181a transcript expression 
was found to be significantly increased in FXS NPCs (Article III: Figure 6B,C). Taken together, the 
results indicate that increase in miR-181a expression could be implicated with reduced GluA2 activity 
leading to enhanced Ca2+ permeability in FXS.  
 
8.3.2 Mechanisms involved in altered differentiation of CP-AMPAR expressing mouse Fmr1-KO NPCs 
Similar to human FXS NPCs, the glutamate-responsive cell populations were increased in mouse FMRP-
deficient cells, at both day 1 and 7 of differentiation (Article III: Figure 3A-D). AMPAR blockers 
completely abolished the KA/AMPA responses in a larger proportion of Fmr1-KO cells at day 7 of 
differentiation (Article III: Figure 3E-F). In addition, the effects of NBQX and Naspm on glutamate-
evoked currents were assessed using whole-cell patch clamp recordings. Confirming the presence of 
AMPARs in differentiating neurospheres, the glutamate-evoked currents were entirely blocked by 
NBQX in both WT and Fmr1-KO cells (Article III: Figure 4A,B). Following the application of Naspm, 
the glutamate-evoked currents showed substantial inhibition in Fmr1-KO neurospheres (Article III: 
Figure 4A,B). Consistent with GluA2-lacking AMPARs exhibiting strong inward rectification (261, 
262), a significant reduction was observed in inward rectification index (I+40/I-60) in FMRP-deficient cells 
(Article III: Figure 4C-E). These results support the findings demonstrating the presence of more GluA2-
lacking AMPARs in Fmr1-KO neurospheres than in controls. Comparable to human FXS NPCs, the 
GluA2 protein expression was reduced, and an abnormal developmental pattern of Gria1 transcript levels 
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was observed in FMRP-deficient neurospheres at day 7 of differentiation (Article III: Figure 5B,D). In 
addition, Gria2 and Gria1 mRNA expression levels were decreased in the adult prefrontal cortex of 
Fmr1-KO mice (Article III: Figure 5E). In summary, the alterations in the functional properties of 
AMPARs, depending on GluA2 subunit expression, demonstrated a novel Ca2+-dependent mechanism 
in FXS NPCs, which might contribute to the hyperexcitability in the FXS brain (263). 
54 
 
9. Discussion 
The present work was centered upon the investigation of glutamate receptor-mediated alterations during 
differentiation of FXS NPCs, as well as the study of the effects of specific mGluR5 and AMPAR 
antagonists on the early aberrances. In addition, the involvement of tPA-mediated processes on neuronal 
migration and activity-dependent changes of Fmr1-KO NPCs were investigated.  
 
9.1 Altered differentiation of FMRP-deficient neural progenitors   
The loss of FMRP results in increased protein synthesis and altered synaptic plasticity, including 
exaggerated mGluR-mediated LTD (9, 14, 15, 214, 264). Excessive activity of group I mGluR signaling 
is thought to underlie the main phenotype of Fmr1-KO mice. The high expression of mGluR5 in the 
active neurogenic zones of pre- and postnatal brains (131) highlights its importance during neurogenesis. 
The [Ca2+]i  responses to DHPG were enhanced in both human and mouse FXS NPCs during early 
differentiation, in line with previous studies showing inappropriate group I mGluR signaling in Fmr1-
KO mice (14). The [Ca2+]i responses to activation of iGluRs were also augmented in human FXS NPCs, 
suggesting the excessive activity of glutamate signaling already at early stages of NPCs differentiation. 
However, the amplitude of  responses to activation of iGluRs are not similarly increased in mouse Fmr1-
KO NPCs, which may reflect progenitor type-dependent differences between human and mouse. Both 
plasmin-dependent and -independent mechanisms of tPA have been proposed to potentiate NMDAR 
signaling (146, 147). For instance, treatment with exogenous tPA increases NMDA-induced [Ca2+]i 
response in mouse cortical neurons (148). The enhanced NMDAR activity of responses can be associated 
with increased tPA expression in Fmr1-KO NPCs. Moreover, dysregulated NMDAR signaling is 
implicated in altered mGluR-mediated LTD in Fmr1-KO mice (193). 
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Previous studies have shown abnormalities in the differentiation of NPCs propagated from human FXS 
fetus and ESCs, embryonic brain, and adult DG of the hippocampus of Fmr1-KO mice (21, 23-25, 44, 
231). Accordingly, enhanced differentiation of cells responsive to activation of glutamate receptors was 
evident in human and mouse FXS NPCs. Notably, the type 2 cell population, which exhibited a prominent 
response to activation of both mGluR and iGluRs was increased in human and mouse FXS NPCs. In 
mouse neurospheres, the cell population was accumulated in zone 2 of the migration area and displayed 
unipolar morphology similar to that of bRG (59, 60). The bRG cells primarily reside in the oSVZ, which 
is present in the developing primate brain but not generally in rodent brain. Even though, rodents lack 
oSVZ, a small subpopulation of unipolar bRG cells reside in SVZ of mouse brain (61, 70). The aRG cell 
divisions can generate bRG cells in a cleavage angle-dependent manner. The vertical aRG cell divisions 
give rise to either a self-renewal aRG or an IP daughter cell (265, 266). In contrast, the division of aRG 
cells with a horizontal cleavage angle generates a self-renewed aRG that inherits apical end foot and bRG 
cell that inherits basal fiber (265, 266). Intriguingly, mouse aRG cells predominately divide with vertical 
cleavage angle, whereas human aRG cells divide both vertically and horizontally in equal proportions 
(265-269). These data suggest that the evolutionary shift from vertical cleavage angle to both vertical 
and horizontal cleavage angles of aRG cells may have contributed to the increased production of bRG 
and expansion of oSVZ in humans. In human FXS NPCs, DHPG-responsive RG and type 3 
subpopulations that showed a substantial response to only iGluRs were increased, but remain unaltered 
in mouse Fmr1-KO cells. Although the 2D cell culture model has proven to be a valuable model for cell-
based studies, it has its limitations. Therefore, further studies on hiPSC-derived organoid cultures are 
necessary to examine the altered differentiation and migration of NPCs in more physiologically relevant 
3D in vitro model.  
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Increased numbers of Tbr2-positive IPs in the VZ/SVZ of the embryonic brain of Fmr1-KO mice (22) 
suggests that loss of FMRP has a great impact on differentiation of NPCs to glutamatergic lineages. 
Saffary et al. showed that the absence of FMRP increases the transition of RG cells to IPs thereby causing 
depletion of RG in the neocortex of Fmr1-KO mice (233). The increased number of Tbr2-positive cells 
and the enhanced differentiation of mGluR/iGluR expressing cells are in line with the increased NeuroD1 
expression reported in NPCs derived from rat cortex (270) and hESCs (45). NeuroD1 is an essential 
regulator of glutamatergic neuronal differentiation (253). During early neuronal development, the 
activity-dependent changes in Ca2+ signaling alter neurotransmitter specification (271). The work 
presented in this thesis demonstrates that the [Ca2+]i responses to high [K+]e were significantly enhanced 
in Fmr1-KO NPCs. These findings implicate that activity-dependent mechanisms contribute to the 
altered glutamatergic differentiation of FXS NPCs. In line with the enhanced neuronal differentiation, 
recent studies demonstrated an increase in activity of transcription factors involved in neuronal 
differentiation (247) and alterations in expression of neurodevelopmental genes (235, 244). In another 
study, Telias et al. found that ESCs lacking FMRP display aberrances in the expression of genes critical 
for normal neurogenesis (231). Taken together, the data suggests that glutamatergic differentiation is 
accelerated in FXS human and mouse NPCs at early developmental stages.  
 
AMPARs are essential for neuronal development, cognitive function and synaptic plasticity (272-274). 
The modulation of AMPAR function and trafficking is crucial for many forms of synaptic plasticity and 
the absence of FMRP appears to have a significant impact on AMPAR-induced synaptic strength and 
excitability (198, 275). The subunit composition of AMPAR is tightly regulated during development and 
in a cell type-dependent manner (276, 277). For instance, changes in subunit composition are involved 
in the developmental switch of CP-AMPARs in pyramidal neurons (278), and synapse-specific 
expression of CP-AMPARs exists in the neocortex (279). Functional GluA2 subunit changes have not 
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previously been reported in FXS, although the GluA1 and GluA2 expression is reduced in the 
somatosensory cortex of Fmr1-KO mice (208). The protein and mRNA expression levels of GluA1 are 
decreased in the cerebral cortex, hippocampus, and amygdala synaptosome extracts of Fmr1-KO mice 
(204, 209). Similarly, a reduction in Gria1 and Gria2 mRNA expression was seen in the prefrontal cortex 
of Fmr1-KO mice. GluA2 protein expression was reduced, and the normal developmental increase in 
Gria1 expression during early differentiation (77) was absent in both human and mouse FXS NPCs, 
suggesting that the AMPAR subunit composition is dysregulated in FXS. Using CP-AMPAR antagonist 
in this study resulted in a reduced proportion of GluA2-lacking AMPARs contributing to the increased 
Ca2+ permeability in human and mouse FXS NPCs. The strong inward rectification in FMRP-deficient 
neurospheres confirmed the delay in the switch of CP-AMPARs to CI-AMPARs in FXS. In FXS hiPSC-
derived neurons, dysregulated RE1 silencing transcription factor (REST) has been shown to suppress 
genes essential for proper neural differentiation and axon guidance (244). REST is required for repression 
of many synaptic genes in NPCs, out of which Gria2 is one of the primary targets (280). The increase in 
REST correlated with reduced GluA2 expression in FXS NPCs observed in the study. Furthermore, the 
absence of FMRP dysregulated the expression of several miRNAs at early NPCs differentiation, in line 
with the previous studies demonstrating altered miRNA expression in FXS (281). The increased miRNA 
expression levels of miR-181a in FXS NPCs suggested that miR-181a contributes to the post-
transcriptional downregulation of GluA2 protein activity leading to increased Ca2+ permeability of 
AMPARs in FXS. In summary, this novel body of work provided a mechanistic insight into the Ca2+ 
dependent mechanisms responsible for enhanced differentiation of FXS NPCs and identified a role for 
dysregulated miRNAs in FXS.  
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9.2 Aberrant neural migration and neurite outgrowth in FXS 
The migration of neurons to their target regions followed by extensions of neurites is essential for the 
normal formation and function of synaptic connections in the CNS. Receptor-mediated or spontaneous 
[Ca2+]i signaling have been shown to associate with neuronal cell differentiation, migration, neurite 
outgrowth, and growth cone dynamics (282-286). The migration of DCX-immunoreactive cells was 
shown to be enhanced and motility pattern was altered in Fmr1-KO NPCs. In addition, neurite outgrowth 
in MAP2-positive cells was reduced in FXS NPCs. The FXS hiPSC-derived neuronal cells have been 
shown previously to display reduced neurite outgrowth and fewer number of neurites per sphere (240, 
242). Treatment with Naspm reduced neurite outgrowth in both control and FXS NPCs, in line with the 
previous studies showing the involvement of CP-AMPARs in the regulation of neurite outgrowth (111). 
Even though the increased CP-AMPAR expressing cells could contribute to alterations of neurite 
outgrowth, other dysregulated mechanisms are likely to be involved too. For instance, GluA1 is a 
regulator of neuronal maturation, and its absence decreases dendritic growth (206, 287). Thus, the 
abnormal developmental expression pattern of Gria1 suggests that GluA1 could contribute to the reduced 
neurite outgrowth in FXS NPCs.  
 
During neurogenesis, nuclei of RG cells display periods of movements between the apical and basal 
surfaces termed as INM (265, 266). It has been speculated that the mechanisms involved in INM of vRG 
cells in VG are similar to the mitotic somal translocation displayed by oRG cells in oSVZ. The speed of 
the salutatory movements of nuclei correlate positively with the amplitude and frequency of Ca2+ 
transients changes (288, 289). The velocity of INM in FMRP-deficient NPCs was significantly increased 
during early NPCs differentiation in this study, consistent with the increased Ca2+ activity in FXS NPCs. 
The accelerated nuclear movement might increase the rate at which the progenitor cells migrate to 
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VZ/SVZ. Altogether, these findings support the role of Ca2+-dependent mechanisms on the neurite 
extension, migration, and nuclear movement in FXS NPCs.  
 
9.3 tPA-mediated effects on Fmr1-KO neural progenitors 
The expression of tPA is found in many neurons and glial cell types, including astrocytes, and microglia 
(143, 290, 291). Substantial experimental evidence demonstrates that tPA mediates neuronal migration 
(292), neurite outgrowth (293), and synaptic plasticity (294) in the CNS. Blocking tPA activity in this 
study normalized the enhanced migration of DCX-immunoreactive Fmr1-KO cells and significantly 
reduced the increased velocity of INM in Fmr1-KO cells. This data in conjunction with the published 
data, suggests that blocking tPA activity retards the migration of neuronal cell populations. In addition, 
treating Fmr1-KO NPCs with tPA-neutralizing antibody reduced the enhanced [Ca2+]i responses to 
depolarization. The aberrances in RG differentiation and migration of FMRP-deficient NPCs are in line 
with previous studies that demonstrated RG defects in FXS (21, 44, 233). Furthermore, tPA 
colocalization with GFAP-positive cells both in NPCs and in the adult brain of Fmr1-KO mice implicates 
its possible role in RG aberrances observed/reported in FXS. It is evident that tPA is a key player for 
both physiological and pathological conditions in the CNS (142). Therefore, further studies on proteolytic 
and nonproteolytic functions of tPA are necessary to understand the role of tPA in the pathophysiology 
of FXS and its potential link to a new therapeutic target in FXS. 
 
9.4 mGluR5-mediated effects on FMRP-deficient neural progenitors 
The genetic reduction and pharmacological block of mGluR5 corrects the main phenotypes of Fmr1-KO 
mice (9, 180, 205, 214, 218, 221) confirming the crucial role of mGluR signaling in the pathophysiology 
of FXS. The study of Dölen et al. supported the use of mGluR antagonists for treatment of FXS by 
demonstrating that 50% reduction in mGluR5 protein levels corrected typical FXS phenotypic features 
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in mice (214). In Fmr1-KO mice, MPEP rescues the audiogenic seizure phenotype (218, 219), reduces 
repetitive-like behavior (219, 220), and normalizes the increased density of immature spines and 
excessive protein synthesis (214, 221). In this study, MPEP treatment normalized the abnormal 
differentiation of type 2 NPC population and the accumulation of these cells in zone 2 of Fmr1-KO 
neurospheres. Treatment with MPEP rescued the altered motility of neuron-like cells and morphological 
defects in FMRP-deficient neurospheres. Furthermore, MPEP administration at E14 normalized the total 
number of Tbr2-positive cells in the SVZ of Fmr1-KO mice, suggesting that by correcting the neuronal 
motility and glutamatergic differentiation, MPEP might have restored the balance of NPC differentiation 
in the brain of Fmr1-KO mice. Although similar alterations in the differentiation of glutamate-responsive 
cell populations were observed, MPEP exhibited differential effects on human and mouse NPCs. In 
contrast to mouse FXS NPCs, MPEP treatment further increased the differentiation of the type 2 cell 
population and reduced the type 3 subpopulation of cells in human FXS NPCs. In addition, treatment 
with MPEP corrected altered differentiation of a cell population that was responsive only to NMDAR 
activation, in line with the previous studies showing the involvement of mGluR-mediated mechanisms 
in dysregulated NMDA signaling (193). The alterations observed between human and mouse NPCs 
populations may reflect differences in the developmental processes. The period of neurogenesis is 
months in human and weeks in mouse, and the differentiation time point selected for investigations may 
represent different developmental stages in human and mouse NPCs cultures. The difference may also 
support the notion that the higher-order brain functions are associated with the neuronal subpopulations 
present in the brain of primates but not in the rat neocortex (266, 295). Despite the fact that neurospheres 
containing heterogonous NPC populations were used to study the altered differentiation in FXS, the 
origin of NPCs and the cell culturing techniques differed between human and mouse. However, the 
hiPSC findings presented in this thesis are in agreement with the enhanced glutamatergic signaling 
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reported in murine models. Therefore, this thesis could be considered as a human-cell based study to 
understand the pathophysiology in FXS patients.   
 
Taken together, this study puts a step forward in understanding the mechanisms involved in altered neural 
differentiation in FXS and emphasize the differences between human, and mouse NPCs differentiation 
(figure 5). The fundamental problem in pre-clinical studies is to model human disease in animals. The 
main cause of failed clinical trials with mGluR5 antagonists in FXS patients (296) might be likely 
because of the timing of the therapy where therapeutic interventions are targeted at too late stages when 
the FXS phenotypes are well established. Considering the fact that any given response in animal models 
does not occur in the same way in humans, the FXS-specific changes identified with hiPSC-derived 
NPCs will provide insights into common interventions that might alleviate the neuropathological 
conditions in other ASD. 
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Figure 5: A schematic representation summarizing the similarities and dissimilarities observed between 
human and mouse NPCs during differentiation of glutamate-responsive cells. Colors in boxes represent 
no change/normalized (green) and augmented (red). CP-AMPAR, calcium-permeable AMPA receptor; 
DHPG, (S)-3,5-dihydroxyphenylglycine; KA, kainic acid; NMDA, N-methyl-D-aspartate. 
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10. Concluding Remarks 
Although extensive research has been carried out using FXS animal models, it remains unclear how 
FMRP regulates neurogenesis and neuronal development in humans. This thesis provides new insights 
into the understanding of FXS NPCs differentiation in the human context. Both human and mouse NPCs 
showed enhanced neuronal differentiation to glutamate-responsive cell populations. However, MPEP 
treatment exhibited differential effects on distinct human and mouse NPCs populations. The differences 
observed between human and mouse cellular models could reflect differential responses of species-
specific NPCs populations or different developmental stages of NPCs. The investigation of mechanisms 
resulting in the enhanced differentiation of CP-AMPARs led to the clue that the increased activity of 
miR-181a might have post-transcriptionally inhibited GluA2 expression in FXS NPCs. In addition, these 
studies demonstrate that tPA could have a role in early RG defects observed in Fmr1-KO NPCs. 
 
The initial pharmacological therapies targeting mechanisms underlying FXS focused on antagonizing 
mGluR5. The results were not very encouraging (296), indicating that there is a need for identification 
of new therapeutic targets to treat FXS. The effectiveness of therapies in humans can be improved by 
further understanding the molecular deregulations in FXS using human-based models and also by 
combining two or more drugs targeting different pathways disturbed in FXS. The findings presented here 
highlight the importance of studies investigating early developmental alterations and provide clues for 
developing new targets. Furthermore, the differences observed between human and mouse NPCs 
populations strongly support the use of human cells to identify molecular mechanisms involved in the 
pathophysiology of FXS and other related neurodevelopmental disorders. 
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